Not Yet RecruitingNot Applicable

DNA Methylation and the Increased Risk of Cervical Cancer Development

2,000 participantsStarted 2025-03-20

Plain-language summary

This study aims to investigate the correlation between reproductive tract microbiota and DNA methylation in cervical epithelial cells, as well as its impact on the development of cervical cancer, through a paired case-control clinical study

Who can participate

Age range15 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18-50 years old, with a history of sexual activity
✓. HPV and TCT tests are performed concurrently in the gynecology clinic
✓. Those with abnormal HPV and TCT test results undergo tissue pathological testing

Exclusion criteria

✕. Pregnant or breastfeeding
✕. Patients with immunological disorders or severe autoimmune diseases, such as AIDS, SLE
✕. Those who have had organ transplants or are currently using immunosuppressive agents
✕. Use of vaginal douching within 48 hours before sample collection
✕. Use of vaginal probiotics within one month before sample collection
✕. Use of vaginal antibiotics or antifungal treatments within one month before sample collection
✕. History of surgery related to cervical intraepithelial neoplasia (CIN), including but not limited to conization of the cervix, LEEP procedures, etc.
✕. Blood samples (avoid sampling during menstruation), insufficient remaining sample volume to support subsequent analysis needs, and samples not stored as required.

What they're measuring

Changes in DNA methylation of cervical epithelial cells

Timeframe: Baseline (enrollment period)

Trial details

NCT IDNCT06859151

SponsorZhujiang Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-30

Contact for this trial

Muxuan Chen, Doctor

+8613580561916 muxuanchen@126.com

View on ClinicalTrials.gov More Cervical Cancer trials